Similar articles

• A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy.

  Sosman JA, Stiff PJ, Bayer RA, Peliska J, Peace DJ, Loutfi S, Stock W, Oldenburg D, Unverzagt K, Bender J, et al. Sosman JA, et al. Bone Marrow Transplant. 1995 Nov;16(5):655-61. Bone Marrow Transplant. 1995. PMID: 8547862 Clinical Trial.
• Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies.

  Vose JM, Bierman PJ, Ruby E, Reed EC, Bishop MR, Tarantolo S, Kessinger A, Armitage JO. Vose JM, et al. Bone Marrow Transplant. 1996 Jun;17(6):951-6. Bone Marrow Transplant. 1996. PMID: 8807099 Clinical Trial.
• Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).

  Bruserud O, Foss B, Petersen H. Bruserud O, et al. Eur Cytokine Netw. 2001 Apr-Jun;12(2):231-8. Eur Cytokine Netw. 2001. PMID: 11399510
• The potential role of granulocyte-macrophage colony stimulating factor (GM-CSF) in cancer chemotherapy.

  Cebon JS, Morstyn G. Cebon JS, et al. Cancer Surv. 1990;9(1):131-55. Cancer Surv. 1990. PMID: 2276111 Review.
• Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: a retrospective analysis.

  Peters BG, Adkins DR, Harrison BR, Velasquez WS, Dunphy FR, Petruska PJ, Bowers CE, Niemeyer R, McIntyre W, Vrahnos D, Auberry SE, Spitzer G. Peters BG, et al. Bone Marrow Transplant. 1996 Jul;18(1):93-102. Bone Marrow Transplant. 1996. PMID: 8832001 Review.